Department of Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Clin Appl Thromb Hemost. 2010 Jun;16(3):266-72. doi: 10.1177/1076029609340901. Epub 2009 Jul 31.
Most patients with malignant diseases are frequently complicated with some type of thrombosis, such as disseminated intravascular coagulation (DIC) or deep vein thrombosis (DVT)/pulmonary embolism (PE).
The cohort and retrospective study was designed to examine the frequency of thrombosis in patients with malignant diseases and to evaluate the efficacy of D-dimer and soluble fibrin (SF) for the diagnosis of thrombosis.
PATIENTS/METHODS: The plasma concentrations of D-dimer and SF were measured in patients with malignant diseases suspected of having thrombosis. D-dimer and SF were measured using a latex aggregation assay.
Thrombosis was observed in 23.3% of the patients with malignant diseases. Disseminated intravascular coagulation was frequently observed in patients with hepatoma, and DVT/PE was frequently observed in patients with colon cancer, lung cancer, and uterine cancer. The plasma levels of D-dimer and SF were increased in malignant diseases, especially hepatoma. Plasma levels of D-dimer and SF were significantly higher in patients with thrombosis in comparison to patients without thrombosis. A receiver operating characteristic (ROC) analysis showed the D-dimer and SF levels to be useful in the diagnosis of thrombosis.
Elevated D-dimer and SF levels might indicate a high risk of thrombosis in patients with malignant disease; however, these assays still need to be standardized.
大多数恶性疾病患者常伴有某种类型的血栓形成，如弥漫性血管内凝血（DIC）或深静脉血栓形成（DVT）/肺栓塞（PE）。
本队列和回顾性研究旨在检查恶性疾病患者血栓形成的频率，并评估 D-二聚体和可溶性纤维蛋白（SF）在血栓形成诊断中的应用。
患者/方法：测量疑似患有血栓形成的恶性疾病患者的血浆 D-二聚体和 SF 浓度。使用乳胶聚集测定法测量 D-二聚体和 SF。
23.3%的恶性疾病患者发生了血栓形成。肝癌患者常发生弥散性血管内凝血，结肠癌、肺癌和子宫癌患者常发生 DVT/PE。恶性疾病患者的 D-二聚体和 SF 血浆水平升高，尤其是肝癌患者。与无血栓形成的患者相比，有血栓形成的患者的 D-二聚体和 SF 血浆水平显著升高。受试者工作特征（ROC）分析表明，D-二聚体和 SF 水平可用于诊断血栓形成。
升高的 D-二聚体和 SF 水平可能表明恶性疾病患者有发生血栓的高风险；然而，这些检测仍需要标准化。
